The yen once fell to 152.74 against the US dollar, and the trend fluctuated after the release of the Bank of Japan's short-term survey. After the release of the Bank of Japan's short-term survey, the yen initially rose slightly, but then weakened. The yen once fell 0.1% against the US dollar to 152.74. The 10-year Japanese government bond futures rose 4 points to 142.49.A spokesman for UnitedHealth Group said that the mother of Mangione, a suspect accused of shooting a company executive, also had no insurance for UnitedHealth.Guotai Junan: The rise of leading enterprises and the downward shift of costs are important features of the steel industry entering a new cycle. Guotai Junan issued a document saying that with the change of demand structure, the demand for plates has steadily increased, and the demand for high-end plates such as automobiles, household appliances, shipbuilding, offshore engineering and energy is strong. The added value and profit per ton of products brought by leading companies' active adjustment of product structure, accumulation of products, R&D drive, continuous capital expenditure and equipment investment have been significantly improved, gradually widening the gap with the industry average gross profit. When the industry is facing the marginal losses of most steel enterprises, leading companies still maintain a high profit level by relying on the cost advantages brought by product differences and management, and the rise and differentiation of industry leaders are emerging. On the other hand, with the gradual increase in the supply side and the difficulty in improving the demand side, iron ore has gradually entered a loose cycle, and the steel cost constraints are expected to gradually improve.
Haitong Securities: The moderate price reduction of traditional Chinese medicine varieties continues. The domestic pharmaceutical industry is expected to set off a wave of mergers and acquisitions. Haitong Securities released a research report saying that the moderate price reduction of traditional Chinese medicine varieties continues. In 2024, the traditional Chinese medicine industry was under pressure due to the pressure of pharmacy terminal sales and inventory pressure, and it is expected to return to a good situation in the next 25 years. In addition, the continuous technological changes in the pharmaceutical industry, the development of IPO to mergers and acquisitions and the promotion of corporate governance optimization at the shareholder level are the main reasons for promoting mergers and acquisitions in the industry. In terms of fields, mergers and acquisitions are expected to occur intensively in sub-sectors such as medical devices, Chinese medicine, medical services, blood products and scientific research services.The troops stationed in Macao are the anchor of maintaining prosperity and stability. This year marks the 25th anniversary of Macao's return to the motherland. Senior Colonel Wu Qian, director of the Information Bureau of the Ministry of National Defense and spokesman of the Ministry of National Defense, said today that the troops stationed in Macao are an important manifestation of national sovereignty. In the past 25 years, especially since the 18th National Congress of the Communist Party of China, the troops stationed in Macao have resolutely implemented the policy of "one country, two systems", conscientiously implemented the Basic Law and the Garrison Law, comprehensively strengthened army building, successfully fulfilled various tasks centered on defense, and effectively safeguarded national sovereignty, security and Macao's prosperity and stability. Looking forward to the future, the troops stationed in Macao will always be loyal guardians assured by the Party and the people, the powerful force of Haojiang trusted by Macao compatriots, and the "anchor needle" for maintaining Macao's prosperity and stability. (CCTV military)Intel executives said that whether to split the company is still an open question. Dave Zinsner, chief financial officer of Intel, said that whether to formally split the factory and product development department is an open question and will be decided by the next leader. After Pat Gelsinger was forced to leave his post earlier this month, Zinsner is now the interim co-CEO. He made the comments when attending the Barclays Technology Conference in San Francisco on Thursday. Michelle Johnston Holthaus, another co-CEO, was also present.
Warner Bros. Discovery will be reorganized into two major departments. Warner Bros. Discovery said that it will be reorganized into two operating departments, one focusing on traditional cable TV business and the other focusing on streaming media and studios, which may pave the way for the company's future transactions. Warner Bros. Exploration said that it will merge its current Max and Discovery+ streaming media services and HBO departments with another department including Warner Bros.' film and television production business.This year's performance is the worst since the epidemic, and Starbucks will reduce the salary increase for its employees. An internal document shows that in view of the company's worst financial performance since the epidemic, Starbucks will reduce the salary increase for its coffee shop employees. According to different qualifications, this year's salary increase is generally between 2% and 3%, while last year's salary increase was at least 3%, and employees who have served for five years or more were at least 5%. The salary increase will take effect on December 30, and employees will see the change of payroll on January 10 or January 17.Onlikon: Compound α-keto acid tablets are planned to be selected for the tenth batch of national centralized drug procurement. Onlikon announced on December 13, and on December 12, the company participated in the bidding for the tenth batch of national centralized drug procurement organized by the National Drug Joint Procurement Office. After the bid opening and evaluation by the Joint Procurement Office, the company plans to select this centralized drug procurement. The indication of that medicine is to prevent and treat the damage caused by metabolic disorder in protein due to chronic renal insufficiency. The drug is a national medical insurance catalogue product, with an annual sales of 218,900 yuan in 2023, accounting for 0.01% of the company's annual operating income in 2023.
Strategy guide 12-14
Strategy guide 12-14
Strategy guide 12-14
Strategy guide 12-14
Strategy guide
12-14
Strategy guide 12-14